Abstract.
The β2-adrenergic receptor (β2AR) is the key target for the β2-agonist drugs used for bronchodilation in asthma and chronic obstructive pulmonary disease. To detect four SNPs with amino acid variations at positions −47T/C (CysBUP19Arg), 46A/G (Gly16Arg), 79C/G (Gln27Glu), and 491C/T (Thr164Ile) in the β2AR gene, we used the electronic microchip assay, denaturing high-performance liquid chromatography (DHPLC), and direct sequencing. Genomic DNA samples were obtained from the blood of 84 Japanese healthy volunteers. The agreement rates of the first data set with the final data (allele calls) were 99.7% (332/333), 99.2% (246/248), and 96.7% (329/340). The percentages of no allele designation (ND) were 2.06% (7/340), 2.75% (7/255), and 0.00% (0/340) for the electronic microchip assay, DHPLC, and direct sequencing, respectively. Furthermore, we found three samples that had a novel haplotype.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Additional information
Received: March 7, 2002 / Accepted: June 10, 2002
Rights and permissions
About this article
Cite this article
Yoshida, N., Nishimaki, Y., Sugiyama, M. et al. SNP genotyping in the β2-adrenergic receptor by electronic microchip assay, DHPLC, and direct sequencing. J Hum Genet 47, 500–503 (2002). https://doi.org/10.1007/s100380200074
Issue Date:
DOI: https://doi.org/10.1007/s100380200074
This article is cited by
-
β-Adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease: a cohort study with hypertensive patients
Hypertension Research (2011)
-
Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans
European Journal of Human Genetics (2005)